Audit Compensation Nominating and Corporate Governance
Larry Ellberger Chairman of the Board Financial Expert Member of Audit Committee   Member of Nominating and Corporate Governance Committee
Keith L. Brownlie Financial Expert Committee Chair for Audit Committee    
Herbert J. Conrad   Member of Compensation Committee Member of Nominating and Corporate Governance Committee
Former President, Roche Pharmaceuticals US

Mr. Conrad has been a director of Celldex since March 2004. He was President of Roche Pharmaceuticals in the United States from 1982 until his retirement in 1993. Mr. Conrad currently serves as Chairman of the Board of Matinas BioPharma Holdings, as a director of Arbutus Biopharmaceuticals and as an advisor to the Seaver Autism Center at Mount Sinai Hospital. He previously served as Chairman of Pharmasset, GenVec and Bone Care International, and he served as a director of Savient Pharmaceuticals and Reliant Pharmaceuticals, where he was a co-founder. Mr. Conrad received B.S. and M.S. degrees from the Brooklyn College of Pharmacy and an honorary doctorate in humane letters from Long Island University.


Holdings: 38,500 shares     View Transactions
James J. Marino,, J.D.   Committee Chair for Compensation Committee  
Harry H. Penner, Jr., J.D., L.L.M. Member of Audit Committee Member of Compensation Committee  
Karen L. Shoos, J.D.     Committee Chair for Nominating and Corporate Governance Committee
Chair of the Board = Chair of the Board Committee Chair = Chair Committee Member = Member Financial Expert = Financial Expert
Chair of the Board = Chair of the Board
Committee Chair = Chair
Committee Member = Member
Financial Expert = Financial Expert

Stock transaction information provided by EDGAR Online. Celldex Therapeutics, Inc. makes no representation or warranty with respect to any of the information contained herein, takes no responsibility for supplementing, updating or correcting any such information and shall have no liability with respect to any such information. This listing does not include derivatives, such as stock option grants or shares purchased through an employee stock purchase plan. For recent transactions, including derivative transactions, see our Section 16 SEC filings page.